Chicago, ILNCT07586046Now EnrollingIRB Ready

HCC - Hepatocellular Carcinoma Clinical Trial in Chicago, IL

Access cutting-edge hcc - hepatocellular carcinoma treatment through this phase 2 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Northwestern University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access hcc - hepatocellular carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hcc - hepatocellular carcinoma treatment provided free

Apply for This Chicago Location

Check if you qualify for this hcc - hepatocellular carcinoma clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This HCC - Hepatocellular Carcinoma Study in Chicago

This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver that have cancer.

Sponsor: Northwestern University

Who Can Participate

Inclusion Criteria

Diagnosis of hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver-dominant metastatic disease not amenable to surgical resection or ablation.
Age ≥18 years.
Child-Pugh class A or B liver function
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Adequate organ and bone marrow function as defined below:
Leukocytes (WBC) ≥ 3,000/mcL
Absolute neutrophil count (ANC) ≥ 1,500/mcL
Hemoglobin ≥ 9 g/dL
Platelets ≥ 50,000/mcL
Total bilirubin ≤ 3.0 mg/dL
AST ≤ 100 U/L, ALT ≤ 120 U/L
Creatinine ≤ 2.0 mg/dL or estimated GFR ≥ 40 mL/min/1.73 m²
Ability to undergo imaging and laboratory evaluations required by the study.
Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

Extrahepatic metastases.
Pregnant or breastfeeding individuals.
Tumors requiring treatment of more than two Couinaud segments.
Known hypersensitivity to gadolinium-based contrast agents.
Contraindications to MRI (e.g., incompatible pacemakers, claustrophobia unresponsive to sedation).
Coagulopathy or clinical instability precluding angiographic intervention.
Prisoners or individuals under legal custody.
Adults unable to consent.
Individuals under 18 years of age.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07586046) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

HCC - Hepatocellular Carcinoma Treatment Options in Chicago, IL

If you're searching for hcc - hepatocellular carcinoma treatment options in Chicago, IL, this clinical trial (NCT07586046) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced hcc - hepatocellular carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hcc - hepatocellular carcinoma clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Chicago, IL

See all liver cancer clinical trials recruiting in Chicago — not just this study.

Browse Liver Cancer Trials in Chicago →

Browse More Trials by Condition

Liver Cancer TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL